Eventide Gilead Fund named WSJ Category King
BOSTON, MA – (Marketwire, July 21, 2014) – The Eventide Gilead Fund (NASDAQ: ETGLX), a mutual fund practicing values-based investing, was named “Category King” by the Wall Street Journal for the one-year period ending June 30, 2014. The Category King award recognizes the top 10 funds in each equity category for one-year total return. The Eventide Gilead Fund ranked #1 in the Mid-Cap Growth category out of 388 funds.
According to Eventide CEO Robin John, the values-based approach of the Fund is believed to be “material” to the Fund’s investing success. Mr. John explained, “Eventide seeks to invest in companies that we believe excel at creating value for all of their stakeholders: customers, employees, supply chain, host communities, environment, and society broadly. But these criteria are not solely about business ethics; we are seeking to understand the vitality, competitive advantage and long-term sustainability of the businesses as shown by their relationship to these stakeholders. We attribute the Eventide Gilead Fund’s outperformance this last year as well as since inception to this viewpoint.”
Over the one-year period, The Eventide Gilead Fund generated a return of +34.87% versus the Russell Mid-Cap Growth Total Return Index of +26.04% and the S&P 500 Total Return Index return of +24.61%, an outperformance of each by 8.83% and 10.26%, respectively. As of June 30, 2014, the Fund had $724.1M in net assets.
The following table shows the Fund’s performance since inception:
| As of 6/30/2014 | YTD return | 1 year return | 3 year annualized return | 5 year annualized return | Since inception (07/08/2008) annualized return |
| Eventide Gilead Fund* | 10.20% | 34.87% | 20.68% | 22.71% | 18.07% |
| Russell Mid-Cap Growth Total Return Index | 6.51% | 26.04% | 14.54% | 21.16% | 11.11% |
| S&P 500 Total Return Index | 7.14% | 24.61% | 16.58% | 18.83% | 9.88% |
Three-year, five-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor’s shares, when redeemed, may be worth more or less than their original cost. Please review the funds’ prospectus for more information regarding the funds’ fees and expenses. Eventide Gilead Fund performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836). The Fund offers A Class shares, which have a maximum sales charge (load) imposed on purchases (as a % of offering price) of 5.75%.
Eventide Gilead Fund expenses: Gross Expenses 1.75%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund’s total annual operating expenses (excluding certain fees and expenses) at 1.42% at least until October 31, 2014.
—
Wall Street Journal rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. The Eventide Gilead Fund ranked #4 out of 347 Mid-Cap
Growth funds (Lipper data) for the 3-yr period based on total returns and #21 out of 313 Mid-Cap Growth funds (Lipper data) for the 5-yr period based on total returns.
The S&P 500 is an index created by Standard & Poor’s Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Past performance is no guarantee of future results and index performance is not indicative of the performance of any Eventide Fund. Investors cannot directly invest in an index; unmanaged index returns do not reflect any fees, expenses or sales charges.
Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
An investor should consider the Funds’ investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds’ prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836) or visit www.eventidefunds.com. Eventide Funds are distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.
Fund Contact:
Jason Myhre, 877-771-EVEN (3836)
4209-NLD-7/18/2014